Detalhe da pesquisa
1.
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
Blood
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557775
2.
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Blood
; 143(2): 152-165, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37832030
3.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Lancet Oncol
; 23(8): 1055-1065, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803286
4.
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.
Am J Hematol
; 97(5): 583-591, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170780
5.
Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma.
Am J Hematol
; 97(12): 1538-1547, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087071
6.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Lancet Oncol
; 22(4): 512-524, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721562
7.
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Br J Haematol
; 195(3): 388-398, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590303
8.
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(11): 1295-1310, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33528286
9.
Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma.
Br J Haematol
; 190(6): 864-868, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510594
10.
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
Br J Haematol
; 189(1): 97-105, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068243
11.
Targeted therapy in mediastinal gray zone lymphoma.
Blood
; 141(22): 2673-2674, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37261857
12.
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Blood
; 131(2): 182-190, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074501
13.
Radiotherapy in mantle cell lymphoma: A literature review.
Hematol Oncol
; 38(3): 223-228, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31873945
14.
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Biol Blood Marrow Transplant
; 25(6): 1158-1163, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30654137
15.
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Blood
; 130(3): 267-270, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28490569
16.
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Blood
; 130(16): 1800-1808, 2017 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28774879
17.
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Blood
; 129(24): 3175-3183, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468797
18.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Lancet Oncol
; 19(2): 257-266, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29276022
19.
The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.
Blood
; 127(17): 2093-100, 2016 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26989206
20.
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.
Blood
; 127(24): 3082-91, 2016 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27020088